# InBrain Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inbrain-pharma

- Industry: Biotechnology
- Headquarters: Loos, France
- Website: www.inbrainpharma.com
- Total disclosed funding: $1.4M
- Latest round: Seed (Feb 15, 2019)
- Investors on record: 2

## About

InBrain Pharma, located in France, is a biotechnology company focused on developing innovative therapies for neurological disorders, particularly advanced Parkinson's disease. Their flagship product, A-Dopamine, revolutionizes treatment approaches.Founded in 2018, InBrain Pharma specializes in therapeutic solutions for neurological conditions. The company has completed 2 deals and recently received EUR 1.8 mn in GRANT funding on May 12, 2025. The total amount raised by InBrain Pharma is EUR 1.2 mn. The company's headquarters is located in Loos, France.InBrain Pharma's core product is A-Dopamine, a revolutionary device-aided therapy designed for the continuous administration of dopamine directly into the brains of patients suffering from advanced Parkinson's disease. This innovative approach addresses significant limitations associated with traditional oral dopamine treatments, such as systemic side effects and inadequate therapeutic efficacy due to dosage restrictions. The therapy is specifically targeted at patients experiencing severe and refractory motor complications due to L-dopa oral treatment, facilitating a more effective and safe management of their symptoms. InBrain Pharma primarily serves patients with advanced Parkinson's disease, healthcare providers, and neurological treatment centers across various geographical markets, focusing on regions with high prevalence rates of neurodegenerative diseases, including North America and Europe.InBrain Pharma's revenue model is structured around partnerships with healthcare institutions and the distribution of its proprietary A-Dopamine therapy. The company collaborates with academic and private entities to facilitate the delivery of its innovative treatment, potentially engaging in B2B transactions with hospitals and specialized clinics that treat neurodegenerative diseases. Revenue is generated through the sale of A-Dopamine devices and associated services, which may include training for healthcare providers and ongoing support. The structure of these transactions involves upfront costs for the devices, with additional charges for any supplementary services offered. The focus on advanced stage Parkinson's disease patients positions InBrain Pharma to generate revenue from a targeted and growing client base that requires specialized care and treatment options.In May 2025, InBrain Pharma secured EUR 1.8 mn in grant funding to support its PERCEPAR project, a therapeutic innovation aimed at enhancing treatment for Parkinson’s disease patients. The company plans to expand its presence in North America and Europe, targeting regions with high needs for advanced neurodegenerative care. The funding will be instrumental in driving the development and implementation of new therapeutic solutions.

## Funding rounds

- Seed, Feb 15, 2019, $1.4M — Siparex, Finovam Gestion

## Investors

- Siparex (https://capitalatlas.ai/funds/siparex) — Seed
- Finovam Gestion (https://capitalatlas.ai/funds/finovam-gestion) — Seed